Blood versus marrow hematopoietic allogeneic graft

Area of Science:

• Hematology and Immunology
• Transplantation Medicine
• Oncology

Background:

• Allogeneic G-CSF-mobilized blood cell transplantation (BCT) is an alternative to allogeneic bone marrow transplantation (BMT).
• BCT offers enhanced engraftment and accelerated hematopoietic recovery but has shown differing immune reconstitution and alloreactivity profiles compared to BMT.
• While acute graft-versus-host disease (GvHD) incidence is similar or lower after BCT, a higher risk of chronic GvHD has been reported.

Purpose of the Study:

• To compare the clinical outcomes and immune reconstitution patterns between BCT and BMT in patients with early leukemia.
• To investigate the immunological differences in grafts and early reconstitution between BCT and BMT.
• To explore potential mechanisms underlying the distinct GvHD profiles observed after BCT.

Main Methods:

• A phase III trial involving 101 patients with early leukemia and HLA-matched sibling donors, randomly assigned to receive either BCT or BMT.
• Prospective examination of immune parameters, including T cell subsets, B cells, NK cells, and monocytes in grafts and peripheral blood post-transplantation.
• Analysis of cytokine production, T cell activation markers, and alloantibody production (anti-A, anti-B, anti-HLA).

Main Results:

• BCT recipients received higher CD34+ cell doses, showed accelerated platelet and neutrophil recovery, and required fewer platelet transfusions.
• Acute GvHD incidence was similar between BCT and BMT, but chronic GvHD occurred more frequently after BCT.
• BCT grafts contained higher numbers of T cells, B cells, NK cells, and monocytes, with less activated T cells compared to BMT grafts. Post-transplant T cell counts were higher and less activated after BCT. Increased alloantibody production, particularly anti-A/B and anti-HLA antibodies, was observed after BCT, especially in minor ABO mismatched settings.

Conclusions:

• Allogeneic G-CSF-mobilized blood cell transplantation leads to distinct hematopoietic and immune reconstitution patterns compared to bone marrow transplantation.
• The increased incidence of chronic GvHD after BCT may be associated with enhanced alloantibody production and specific immune cell profiles in the graft.
• While BCT accelerates hematologic recovery, careful monitoring for chronic GvHD and alloantibody-related complications is warranted.